Influence of the Genetic Polymorphisms in the 5′ Flanking and Exonic Regions of CYP2C19 on Proguanil Oxidation

被引:12
作者
Satyanarayana, Chakradhara Rao Uppugunduri [1 ]
Devendran, Anichavezhi [1 ]
Jayaraman, Muthukumaran [3 ]
Mannu, Jayakanthan [3 ]
Mathur, Premendu P. [3 ]
Gopal, Shewade Deepak [1 ]
Rajagopal, Krishnamoorthy [2 ]
Chandrasekaran, Adithan [1 ]
机构
[1] Jawaharlal Inst Postgrad Med Educ & Res JIPMER, Dept Pharmacol, Pharmacogenom Lab, Pondicherry 605006, India
[2] Hop Robert Debre, INSERM, U763, F-75019 Paris, France
[3] Pondicherry Univ, Ctr Bioinformat, Pondicherry, India
关键词
CYP2C19; promoter; transcription; variant alleles; transcription factor; phenotype; docking; South Indian; S-MEPHENYTOIN; 4-HYDROXYLATION; IN-VITRO; C/EBP-ALPHA; OMEPRAZOLE; METABOLISM; GENOTYPE; PHENOTYPE; ALLELES;
D O I
10.2133/dmpk.24.537
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP2C19 is a polymorphic enzyme which metabolizes several clinically important drugs including proguanil. Variation in the 5' regulatory region may influence CYP2C19 activity. This study evaluates the relationship between proguanil metabolic ratio and genetic variations of CYP2C19 in a South Indian population. Fifty unrelated healthy subjects were genotyped for CYP2C19 *2 and *3 alleles and the 5' flanking region of CYP2C19 was sequenced. Plasma concentrations of proguanil and cycloguanil were estimated by reverse phase HPLC after single oral doses (200 mg) of proguanil. In silico docking analysis of transcription factors binding to its sites in CYP2C19 5' regulatory region was performed. The mean metabolic ratios (proguanil/cycloguanil) were highest in *1/*2 or *1/*3 subjects and in *2/*2 or *2/*3 as compared to *1/*1 subjects. Subjects with promoter region variation -98T > C showed decrease in the metabolic ratios irrespective of other variation, which may explain the deviation from the genotype-phenotype association of CYP2C19. In silico analysis predicted alteration in the interaction of transcription factors to their binding sites in the presence of variant alleles. The results of this study would be useful in predicting interindividual differences in the metabolism of substrates of CYP2C19.
引用
收藏
页码:537 / 548
页数:12
相关论文
共 50 条
  • [11] Effects of CYP2C19 Genetic Polymorphisms on Atomoxetine Pharmacokinetics
    Choi, Chang-Ik
    Bae, Jung-Woo
    Lee, Yun-Jeong
    Lee, Hye-In
    Jang, Choon-Gon
    Lee, Seok-Yong
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (01) : 139 - 142
  • [12] Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites
    Lee, Hye-In
    Byeon, Ji-Young
    Kim, Young-Hoon
    Lee, Choong-Min
    Choi, Chang-Ik
    Jang, Choon-Gon
    Bae, Jung-Woo
    Lee, Yun Jeong
    Lee, Seok-Yong
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (11) : 1417 - 1426
  • [13] Influence of CYP3A and CYP2C19 Genetic Polymorphisms on the Pharmacokinetics of Cilostazol in Healthy Subjects
    Yoo, H-D
    Park, S-A
    Cho, H-Y
    Lee, Y-B
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (03) : 281 - 284
  • [14] Clopidogrel Inhibits CYP2C19-Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms
    Chen, B. L.
    Chen, Y.
    Tu, J. H.
    Li, Y. L.
    Zhang, W.
    Li, Q.
    Fan, L.
    Tan, Z. R.
    Hu, D. L.
    Wang, D.
    Wang, L. S.
    OuYang, D. S.
    Zhou, H. H.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (05) : 574 - 581
  • [15] Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behcet's Disease
    Goktas, Mustafa Tugrul
    Karaca, Ragip Ozgur
    Kalkisim, Said
    Cevik, Lokman
    Kilic, Levent
    Akdogan, Ali
    Babaoglu, Melih O.
    Bozkurt, Atilla
    Bertilsson, Leif
    Yasar, Umit
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 (04) : 266 - 271
  • [16] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers
    Shao, H.
    Ren, X. M.
    Liu, N. F.
    Chen, G. M.
    Li, W. L.
    Zhai, Z. H.
    Wang, D. W.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (03) : 351 - 360
  • [17] Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations
    Allabi, AC
    Gala, JL
    Desager, JP
    Heusterspreute, M
    Horsmans, Y
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) : 653 - 657
  • [18] Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians
    Kohlrausch, Fabiana B.
    Carracedo, Angel
    Hutz, Mara H.
    MOLECULAR BIOLOGY REPORTS, 2014, 41 (03) : 1453 - 1460
  • [19] The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects
    Tan, Bo
    Zhang, Yi-Fan
    Chen, Xiao-Yan
    Zhao, Xiao-Hua
    Li, Guo-Xin
    Zhong, Da-Fang
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (02) : 145 - 151
  • [20] Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population
    Hu, Li-Ming
    Dai, Da-Peng
    Hu, Guo-Xin
    Yang, Jie-Fu
    Xu, Ren-Ai
    Yang, Li-Ping
    Qian, Jian-Chang
    Ge, Ren-Shan
    Cai, Jian-Ping
    PHARMACOGENOMICS, 2012, 13 (14) : 1571 - 1581